EverSource Wealth Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

EverSource Wealth Advisors’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.11K	Sell	35 -42	-55%	-$2.33K	﹤0.01%	3704
2026 Q1	$4.48K	Sell	77 -135	-64%	-$6.22K	﹤0.01%	3317
2025 Q4	$9.5K	Buy	212 +172	+430%	+$7.22K	﹤0.01%	2826
2025 Q3	$1.61K	Buy	40 +14	+54%	+$493	﹤0.01%	3585
2025 Q2	$814	Sell	26 -32	-55%	-$1.04K	﹤0.01%	3781
2025 Q1	$1.95K	Buy	58 +28	+93%	+$1.06K	﹤0.01%	2944
2024 Q4	$1.18K	Sell	30 -388	-93%	-$16K	﹤0.01%	2909
2024 Q3	$16.5K	Buy	418 +347	+489%	+$14K	﹤0.01%	1594
2024 Q2	$3.06K	Sell	71 -93	-57%	-$3.72K	﹤0.01%	2404
2024 Q1	$6.67K	Buy	164 +118	+257%	+$5.43K	﹤0.01%	1902
2023 Q4	$2.12K	Buy	+46	New	+$1.63K	﹤0.01%	2147

Other funds holding XENE

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

EverSource Wealth Advisors's XENE Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Xenon Pharmaceuticals (XENE) stake by 55% in Q2 2026, selling an estimated $2.33K and leaving 35 shares worth $2.11K. The position accounts for ﹤0.01% of the portfolio, ranked #3704.

EverSource Wealth Advisors first reported a position in XENE in Q4 2023 and has held it in 11 quarters since. The position peaked at $16.5K in Q3 2024. 66 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

EverSource Wealth Advisors held 35 shares of Xenon Pharmaceuticals worth $2.11K as of Q2 2026.
EverSource Wealth Advisors sold 42 Xenon Pharmaceuticals shares in Q2 2026, an estimated $2.33K.
Xenon Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3704 holding.
EverSource Wealth Advisors first reported a position in Xenon Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
EverSource Wealth Advisors's Xenon Pharmaceuticals position peaked at $16.5K in Q3 2024.
66 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.